PHACTR2

Across TCGA pan-cancer cohorts, PHACTR2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PHACTR2 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PHACTR2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PHACTR2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and COAD are the cancer types where PHACTR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.925	0.705	.003	47	view →
CCRCC	OS	Tertile	All	0.917	0.765	.005	15	view →
COAD	DFS	Median	III,IV	1.000	0.820	.033	6	view →
GBM	OS	Tertile	All	0.907	0.629	.018	3	view →
LUAD	DFS	Tertile	All	0.780	0.519	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PHACTR2–PDAC (OS)

Open the PDAC breakdown →